UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh

Simply Wall St.09:36

uniQure (NasdaqGS:QURE) faces multiple securities class action lawsuits focused on disclosures around its AMT-130 gene therapy program. Federal health officials have criticized the company for alleged...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618905241?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-12 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618905241","market":"us","top_or_hot":-1,"title":"UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh","media":"Simply Wall St.","content":"<div>\n<p>uniQure (NasdaqGS:QURE) faces multiple securities class action lawsuits focused on disclosures around its AMT-130 gene therapy program. Federal health officials have criticized the company for alleged...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-faces-amt-130-scrutiny-as-fda-shifts-and-lawsuits-we\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 09:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-faces-amt-130-scrutiny-as-fda-shifts-and-lawsuits-we><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>uniQure (NasdaqGS:QURE) faces multiple securities class action lawsuits focused on disclosures around its AMT-130 gene therapy program. Federal health officials have criticized the company for alleged...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-faces-amt-130-scrutiny-as-fda-shifts-and-lawsuits-we\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4219","symbol_name":"电信塔房地产信托","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-faces-amt-130-scrutiny-as-fda-shifts-and-lawsuits-we","article_id":"2618905241","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-faces-amt-130-scrutiny-as-fda-shifts-and-lawsuits-we","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618905241","pubTimestamp":1773279364,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"uniQure (NasdaqGS:QURE) faces multiple securities class action lawsuits focused on disclosures around its AMT-130 gene therapy program.\nFederal health officials have criticized the company for alleged data manipulation tied to AMT-130.\nThe FDA has withdrawn support for a Biologics License Application for AMT-130, complicating the program's regulatory path.\nUpcoming changes in FDA leadership are expected to affect how AMT-130 and related filings are reviewed.\n\nThese developments arrive at a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4219":"电信塔房地产信托","BK4588":"碎股","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","QURE":"uniQure N.V.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","AMT":"美国电塔","BK4581":"高盛持仓","BK4084":"特种房地产投资信托","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","BK4554":"元宇宙及AR概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"随着FDA的转变和诉讼的影响，UniQure面临AMT-130审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":0.9,"LABU":1.5,"AMT":1.5},"content_text":"uniQure (NasdaqGS:QURE) faces multiple securities class action lawsuits focused on disclosures around its AMT-130 gene therapy program. Federal health officials have criticized the company for alleged data manipulation tied to AMT-130. The FDA has withdrawn support for a Biologics License Application for AMT-130, complicating the program's regulatory path. Upcoming changes in FDA leadership are expected to affect how AMT-130 and related filings are reviewed.  These developments arrive at a sensitive time for uniQure, with the stock at $17.56 and a 94.2% gain over the past week, alongside a 31.6% return over the past year. Those moves sit against weaker figures over longer windows, including a 24.9% decline year to date and a 49.2% decline over five years, which already pointed to a mixed track record for shareholders. For investors following NasdaqGS:QURE, the combination of regulatory pressure, litigation risk, and leadership turnover at the FDA creates a more complicated backdrop for assessing AMT-130. The rest of this article focuses on how these events could influence timelines, risk perception, and the role of AMT-130 in the broader uniQure story. Stay updated on the most important news stories for uniQure by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on uniQure. NasdaqGS:QURE 1-Year Stock Price Chart Is uniQure's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At US$17.56 vs an average analyst target of about US$38.47, the price sits roughly 54% below consensus, which suggests expectations are higher than the current quote. ❌ Simply Wall St Valuation: Our DCF valuation status is marked as unknown, so there is no clear undervalued or overvalued signal to lean on here. ❌ Recent Momentum: The 30 day return of about 32.6% decline highlights weak recent momentum, even after the sharp weekly move mentioned earlier.  There is only one way to know the right time to buy, sell or hold uniQure. Head to Simply Wall St's\ncompany report for the latest analysis of uniQure's Fair Value. Key Considerations  📊 Regulatory scrutiny around AMT-130, the withdrawn BLA path and lawsuits all push the story toward higher execution risk on a single pivotal program. 📊 Watch how the FDA leadership change, trial disclosures and any updates on AMT-130 data quality line up with the wide analyst target range of US$8.95 to US$95.18. ⚠️ The most pressing risk here is that legal and regulatory outcomes around AMT-130 could affect timelines, costs and investor confidence at the same time as the share price remains highly volatile.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete uniQure analysis. Alternatively, you can check out the\ncommunity page for uniQure to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if uniQure might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618905241","isCrawlerRequest":true}